Most men arrive at the clinic with the same mental model: in the bathroom cabinet, behind the mouthwash, there is a small foil sleeve of blue pills. When they need them, they take one. When they don't, they don't. It is a transaction, not a treatment plan. So when we mention shockwave therapy, the question that follows is almost always the same — but doesn't the pill already work?
It usually does. That's not the question. The question is what you want the treatment to actually do.
What the pills do, mechanically
Sildenafil, tadalafil, vardenafil and avanafil are all PDE5 inhibitors. They don't cause an erection. What they do is prevent the breakdown of a small signalling molecule — cyclic GMP — that your body releases in the corpus cavernosum during arousal. With cGMP hanging around longer, the smooth muscle in the penile arteries stays relaxed, blood fills the lacunar spaces, and an erection becomes possible.1
This is why they don't work if you take one and read a spreadsheet. There needs to be arousal first. The drug only amplifies the signal that's already there.
Pooled trial data has put the response rate for PDE5 inhibitors at roughly 70–80%, depending on the underlying cause of the ED and the dose used.1,2 Which is excellent — but it also means that something like one in three men either gets a partial response or no useful response at all. And among the responders, the pill has to be taken every time. It is not, in any meaningful sense, treating the underlying condition. It is replacing a missing function on demand.
PDE5 inhibitors are a remarkably safe, well-studied class of drugs that work for most men, most of the time. They are not, however, a cure. They are a workaround for an arterial signalling pathway that has stopped doing its job. If you stop taking them, you're back where you started.
What shockwave does, mechanically
Low-intensity extracorporeal shockwave therapy — Li-ESWT, in the literature — is a different category of intervention. A handheld applicator delivers focused acoustic pressure waves through the skin into the erectile tissue. The energy is low enough that nothing is broken, cut or thermally damaged. What it does, in animal and human studies, is induce a controlled biological response in the tissue beneath.3,4
That response includes upregulation of vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS), proliferation of endothelial cells, and what the foundational work by Vardi and Gruenwald described as neovascularization — the formation of new microvessels in tissue that had become hypoperfused.3,4 There is also evidence of progenitor cell recruitment, though the mechanistic story there is still being filled in.
In plain English: the pills make the arteries you have work harder. Shockwave is attempting to make you have better arteries.
How strong is the evidence?
This is where honesty matters. Multiple meta-analyses since 2022 have found that Li-ESWT produces statistically significant improvements on the IIEF-EF score and the Erection Hardness Score compared with sham treatment, particularly in men with mild-to-moderate vasculogenic ED.5,6 Effects appear to last in the range of months rather than weeks.
The 2025 updated meta-analysis of randomized trials including roughly 882 men with vasculogenic ED reported significant benefit over sham.5 A 2024 British Medical Bulletin review was more cautious, concluding that heterogeneity in protocols, devices and patient selection makes a single "standard of care" statement premature.6
Guidelines reflect that mixed picture. The European Association of Urology has acknowledged that the data suggest shockwave can ameliorate ED and reduce the need for more invasive treatments. The American Urological Association, in its 2018 guideline (reaffirmed since), classifies Li-ESWT as investigational — a deliberate, conservative word meaning promising, not yet standard.7
Who responds to what
The candidate profiles for these two treatments are not identical, and treating them as interchangeable misses the point.
Men with mild-to-moderate vasculogenic ED — typically the metabolic-syndrome pattern: some hypertension, a creeping waistline, a family history of cardiovascular disease, and erections that have softened over a few years — are the ones who consistently do best on shockwave in the published trials.5 They have arterial inflow that is impaired but not destroyed. There is something for the tissue response to act on.
Men who have responded well to PDE5 inhibitors but want to reduce their dependence on the pill are also reasonable candidates. So are men who are partial PDE5 responders — they get something from the pill, just not enough.
Shockwave is a less convincing first-line choice for men with severe neurogenic ED (after radical prostatectomy with bilateral nerve damage, for instance), for men with significant Peyronie's disease, or for men whose primary problem is psychogenic. None of those scenarios disqualify a man from consideration, but the conversation gets more individual.
When combining them is actually the right call
The most clinically useful question is rarely pill or shockwave. It is what sequence, and for how long.
There is a small but consistent body of evidence on PDE5 non-responders — men for whom even tadalafil 20 mg has stopped producing a usable erection. In several studies, a course of Li-ESWT shifted a meaningful fraction of these men back into the responder category. One twelve-month follow-up reported effective response in roughly 60% of previously unresponsive patients, with most maintaining the response.8 A separate trial reported response in 58% of non-responders at 8 weeks, rising to 71% by week 16.9
That is a more useful outcome than a headline figure suggests, because PDE5 non-responders are often the men staring down the next tier of interventions — intracavernosal injections, vacuum devices, implants. Anything that reopens the door to a tablet is meaningful.
| Dimension | PDE5 inhibitors (sildenafil, tadalafil) | Low-intensity shockwave (Li-ESWT) |
|---|---|---|
| What it targets | The signalling pathway, in the moment | The underlying microvasculature, over weeks |
| When it works | 30 minutes to several hours after dosing | Effect develops over weeks; sustained for months |
| Response rate | ~70–80% overall | Significant benefit in mild–moderate vasculogenic ED; variable in severe cases |
| Treats the cause? | No — replaces the function | Aims to improve the tissue itself |
| Use ongoing? | Yes, every time (or daily low-dose) | Course-based; periodic top-ups in some protocols |
| Side effect profile | Headache, flushing, nasal congestion, GI; nitrate interaction | Minimal in published trials; mild transient discomfort |
| Guideline status | First-line; high evidence quality | Considered restorative; investigational per AUA, accepted with caveats per EAU |
What a session course actually looks like
Protocols vary by device and clinic. A common evidence-based regimen is twice-weekly sessions for four to six weeks, with each session delivering shockwaves to multiple sites along the penile shaft and the crura.10 Each session takes roughly 15–25 minutes. There is no anaesthesia. Most men describe the sensation as a brisk, palpable tapping — not painful, sometimes mildly uncomfortable for a few seconds. You walk out, and you drive home.
The effect is not immediate. The biology being targeted — endothelial proliferation, growth-factor signalling, microvascular remodelling — operates on a timescale of weeks. In the studies, men typically begin reporting change between weeks four and eight, with improvements often continuing for several months after the course ends.
If you are taking a PDE5 inhibitor when you start shockwave, you usually continue. The intent isn't a binary swap. It is to widen the response — to recover the part of the pathway the pill is currently leaning on, so the pill (when needed) has more to work with.
None of this replaces a proper conversation about why the erections are softening in the first place. That conversation, ideally, includes a blood pressure cuff, a lipid panel, an A1c, and an honest question about sleep, stress and weight. ED is rarely a standalone problem. Treating it well usually means treating more than it.